First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

September 15, 2022

Study Completion Date

December 26, 2022

Conditions

Not Determined

Interventions

DRUG

BGB-23339

Administered orally as a tablet

DRUG

Placebo

Administered orally as a tablet

Trial Locations (3)

The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao

Q PHARM, Herston

Nucleus Network, Melbourne